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Aberrant glycosylation during carcinogenesis results in altered glycan expression on oral cancer cells. The
objective of this study was to detect this atypical glycosylation via imaging of fluorophore-conjugated lectins.
Paired normal and tumor tissue from seven patients with oral squamous cell carcinoma were investigated for sialic
acid expression via the legume protein wheat germ agglutinin (WGA). Fluorophore (Alexa Fluor 350 and Alexa Fluor
647) conjugated WGA was topically applied to the tissue samples and imaged using a custom wide-field
fluorescence imaging system. All seven patients had histologically confirmed disease with 6/7 exhibiting
squamous cell carcinoma and 1/7 exhibiting dysplasia. Fluorescent data collected from all patients demonstrated
that fluorophore conjugated WGA could distinguish between pathologically normal and diseased tissue with the
average signal-to-noise ratio (SNR) among all patients being 5.88 (P = .00046). This SNR was statistically
significantly higher than the SNR from differences in tissue autofluorescence (P = .0049). A lectin inhibitory
experiment confirmed that lectin binding is molecularly specific to overexpressed tumor glycans and that
fluorescence is not due to tissue optical properties or tissue diffusion differences. These results illustrate that
changes in tumor glycan content of oral neoplasms can be detected with optical imaging using topically applied
fluorescently labeled WGA. Lectin targeting of oral lesions using optical imaging may provide a new avenue for the
early detection of oral cancers.
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Oral cancer, which includes cancers of the lips, tongue, cheeks, floor
of the mouth, hard and soft palate, sinuses, and pharynx (throat), is
the sixth most common cancer nationally and the third most
prevalent cancer in developing countries [1–3]. Oral cancer's five year
survival rate has slightly increased over the past four decades to 65%
in 2009; however, unfortunately its increase has not improved as
much as other cancers over the same period [3]. This is because
clinicians face considerable challenges in visually identifying oral
neoplasia at an early stage, leading to many diagnoses occurring late in
neoplasia progression [3,4].
Currently disease progression, surgical margins, metastasis and
extent of invasion are decided based on diagnostic methods such asX-rays, CT scans or PET images carried out prior to surgery [5,6].
These techniques, though clinically useful, have safety concerns,
cannot predictably detect tumors less than 1 cm in diameter
(equating to greater than 1 million cancerous cells), and cannot be
generated in real time to guide the surgeon intra-operatively.
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to the problem of oral lesion detection (i.e. ViziLite, VELscope,
Trimira, OralCDx, etc.). However, the effectiveness of these
technologies is inconsistent [5,7]. The literature suggests that these
modalities fail to noticeably improve the detection of oral carcinomas
from standard head and neck examinations routinely performed by
physicians [7]. A major reason for the inconsistency, poor specificity
and inability to detect earlier stage cancer is the oversight of these
technologies to target advanced stage anatomical changes instead of
early stage molecular level alterations.
Optical molecular imaging provides a non-invasive, in vivo, rapid
and cost effective method to detect early molecular level changes in
neoplastic tissue, based on its ability to specifically analyze molecules
of interest. More importantly, optical molecular imaging can be
performed with minimum training, increasing its potential to be used
in the general physicians' office. Possible targets for optical imaging
are the glycoproteins and glycolipids on the cell surface. These cellular
glycomolecules are completed during the post-translational event
called glycosylation, which is known to be abnormal in human disease
progression such as carcinogenesis and metastasis [8–10]. This
irregular glycosylation results in varying glycosyl residues on the cell
surface during pathological changes, highlighting the clinical
importance of this alteration as a potential target by which to detect
oral cancer.
A prime example of aberrant glycosylation in carcinogenesis is the
overexpression of sialyl Lewis A and sialyl Tn antigen in cancers of the
pancreas, colon, stomach and esophagus [11,12]. Moreover, increased
sialytransferases and sialic acid content on cell glycoconjugates has
long been linked to oral cancer and malignant transformation
[13,14]. Increased sialic acid content can reach up to 10e+09 sialic
acid residues per tumor cell [15]. Further, Rajpura et al. showed
statistically significantly higher levels of sialic acid in oral cancer patients
compared to normal patients (63.70mg/dl versus 30.25mg/dl,
respectively; P b .001, 41 patients) [16]. Silvia et al. and Joshi et al.
showed similar significant results for sialic acid overexpression in oral
cancer patients [17,18].
Specific glycan changes can be targeted using lectins. Lectins are
proteins or glycoproteins of non-immune origin that bind non-
covalently to specific oligosaccharide chains extending extracellularly
from glycoproteins or glycolipids [19]. Lectins exhibit high specificity
in recognizing their specific sugar moieties, and thus are useful
analytical tools to study the alterations in cell surface carbohydrates in
diseased stages [15,19–21]. The other advantages of using lectin
probes are the ease of production due to their abundance,
inexpensiveness, ease of labeling with fluorescent probes, heat
stability, stability at low pH, and low toxicities as many are part of
the normal human diet [22].
As sialic acid residues are overexpressed during carcinogenesis, an
appropriate lectin probe specific to sialic acid could provide an
advantageous biomarker for oral cancer detection. One particular lectin
of interest is the legume wheat germ agglutinin (WGA), which is a
carbohydrate-binding lectin of approximately 36 kDa that selectively
recognizes sialic acid and N-acetylglucosaminyl sugar residues
[11,14,22]. Furthermore, conjugation of this lectin with a fluorophore
could provide an effective non-invasive in vivo screening method to
visualize premalignant and malignant oral lesions in real time.
The objective of our study was to establish a preclinical screening
technique that targets an intrinsic fluorophore, nicotinamide adenine
dinucleotide (NAD+/NADH), and sialic acid expression, usingfluorescent conjugated WGA, to screen for oral cancers. This proof-
of-concept preclinical study will be used to guide later clinical
evaluation studies.Materials & Methods
Clinical Sample Set
Freshly extracted tissue samples were obtained either from patients
diagnosed with oral cancer or from scalpel biopsies acquired from
patients suspected of having oral cancer. In addition, punch biopsies
were acquired from patients suspected to have oral cancer, which
entered the study via the walk-in clinic. All seven patients gave their
written informed consent to participate, and the study was reviewed
and approved by the Institutional Review Boards at the University of
Minnesota and the Mazumdar Shaw Cancer Center in Bangalore,
India. Paired biopsies of clinically normal and abnormal oral mucosa
were acquired with patient morbidity in mind, and did not deviate
from normal clinical practice (Figure 1). Normal tissue biopsies either
came from tissue adjacent to the surgical margin or from a slight
extension of suspicious lesion margin (Figure 1). Upon extraction,
tissue samples were placed in 1× phosphate buffered saline (PBS)
(Sigma Aldrich, Milwaukee, WI) to prevent dehydration and then
were immediately used for testing. All materials were used as received,
unless noted otherwise.
Topical Application of Lectin Probe
To initially demonstrate the efficacy of fluorescently labeled lectins,
Alexa Fluor 647 conjugated WGA (AF647-WGA) (Invitrogen,
Carlsbad, CA) was used to target sialic acid residues on the cells'
surfaces. This specific fluorophore was used since tissue autofluores-
cence is minimal in the far red and near-infrared spectrums [23].
Specifically, AF647-WGA (5μM titration in 1×PBS, pH 7.4) was
topically applied to the tissue samples in the presence of 10 v/v%
dimethylsulfoxide (DMSO) (Sigma Aldrich, Milwaukee, WI).
DMSO was used as a permeation enhancer to improve delivery of
the lectin conjugate through the epithelium of the tissue samples.
Alexa Fluor 350 conjugated WGA (AF350-WGA) (Invitrogen,
Carlsbad, CA) (20μM titration in 1×PBS, pH 7.4, and 10 v/v%
DMSO) was then used to demonstrate that analogous results could be
obtained in the UV spectrum. The molar concentration of AF350-
WGA was increased compared to AF647-WGA to overcome possible
autofluorescence background signals. Furthermore, the use of a UV
fluorophore allowed for the direct comparison of tissue autofluores-
cence to the fluorescence of AF350-WGA binding. Briefly, tissue
autofluorescence in the UV spectrum at 365nm is largely due to an
endogenous fluorophore called nicotinamide adenine dinucleotide
(NAD+/NADH) [24,25]. This physiologically important coenzyme
is interesting in the fact that its reduced form (NADH) is fluorescent
at 365nm whereas its oxidized form (NAD+) is not. Due to changes
in metabolism during oral carcinogenesis, oral cancer cells have lower
levels of NADH [24,25]. To establish an autofluorescence back-
ground value at 365nm, epi-illumination (reflectance) images were
acquired from the tissue samples under narrow band illumination of
UV light using a 365nm ± 7.25nm LED (Opto Technology Inc.,
Wheeling, IL).
Both Alexa Fluor conjugated WGA molecules were subjected to
the following protocols which were slightly modified according to the
tissue type of the patients. Pilot experiments were conducted to
Figure 1. Schematic representation of tissue processing and imaging. The figure represents the surgical resection of abnormal
and control tissue (1), pre-incubated in PBS (2) and in WGA-fluorophore for an hour (3). The samples are subsequently washed in
PBS 3 times (4) and then imaged using a custom designed optical imaging system capable of multispectral epi-illumination
(reflectance) imaging (5).
Table 1. Excitation and emission filters used in this study.
365nm High Flux LED 630nm High Flux LED
Excitation 360nm ± 5nm bandpass 640nm ± 5nm bandpass
Fluorescence 400nm longpass and 450nm ± 20nm
bandpass
650nm longpass and 680nm ± 5nm
bandpass
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staining (data not shown).
For biopsies. The tissue samples were stained with 0.5 ml to 2ml
of WGA fluorescent probe and incubated for one hour at 37°C. The
tissue samples were then washed three times in succession, the first
time with 30 ml 1x PBS in 10 v/v%DMSO, and the second and third
times with 30 ml 1x PBS.
For complete resection samples. The tissue was stained with 4 ml of
WGA fluorescent probe and incubated for one hour at 37°C. The tissue
was then washed three times in succession, the first time with 100ml 1x
PBS in 10 v/v%DMSO, and the second and third times with 100ml 1x
PBS. The larger volume used for resected tissue was necessary as these
tissue samples were physically larger than the biopsies.
Lastly, the molecular specificity of the WGA binding was assessed
by pre-incubating the AF350-WGA with its inhibitory sugar N-acetyl
glucosamine at a concentration of 0.5M. This was performed for 30
min at 37°C. The uninhibited and inhibited conjugated AF350-
WGA were then applied to different cancerous biopsy samples taken
from the same surgical site and incubated for one hour at 37°C. A
cancerous biopsy that was not incubated with anyWGA was also used
as a control for comparison purposes. The normal tissue sample only
received uninhibited AF350-WGA, and was incubated simultaneous-
ly with the cancerous biopsies. Tissue samples were then washed as
stated previously for biopsies and imaged as described in the next
section. This inhibition procedure was derived from similar lectin
inhibition procedures established in the literature [8,26–28].
Optical System
Following incubation in theWGA-fluorophore DMSOmixture and
washing, tissue surface sialic acid expression in normal and neoplastic
oral tissues was measured using high-resolution fluorescence imaging.
Reflectance and fluorescence images were acquired using a custom
designed optical system. The imaging system (Figure 1) allowed for epi-
illumination data acquisition to be obtained at multiple wavelengths,specifically white light illumination, UV (365nm ± 7.25nm) and red
(630nm ± 10nm). Excitation illumination was performed with high
intensity light emitting diodes (LEDs) (Opto Technology Inc.,
Wheeling, IL) collimated and directed to evenly illuminate the entire
field of view (10 cm × 10 cm). Conversely, due to space constraints, the
white fluorescent light was mounted at the rear of the optical system.
The high intensity LEDs were powered using constant current LED
drivers (LuxDrive a division of LEDdynamics Inc, Randolph, VT), so
that invariable radiant power could be achieved. Paired sets of biopsies
were imaged together to ensure they received identical imaging
conditions (i.e. detector gain and radiant illumination power). Photons
generated within the tissue samples were then detected by a scientific
CCD camera (Coolsnap HQ, Photometrics, Tucson, AZ) using the
appropriate bandpass and longpass filters (Thorlabs, Newton, NJ). The
filters for each combination have been summarized in Table 1. Lastly, a
Canon PowerShot A3100 IS digital camera (Canon U.S.A. Inc.,
Melville, NY) was mounted within the optical system to capture
fluorescent images that would more accurately demonstrate the
conditions observed within the clinical setting without filtering.
Fluorescence overlay images were created by superimposing the
fluorescence images over the white light images; this was performed
for registration and clinical relevance.
Quantification of Imaging Data
Wide-field fluorescence images of the oral tissue samples obtained
before and after incubation were quantitatively analyzed using ImageJ
(NIH, Bethesda, MA) to calculate the mean fluorescence intensity
Figure 2. Representative white light and fluorescence overlay images of complete resections and biopsies from the same patient. The
freshly resected specimen (A & B) and biopsies (C & D) were imaged under white light (A & C) and fluorescence (B & D). The whole
specimen was labeled with AF647-WGA (B), while the biopsies were labeled with AF350-WGA (D). Both fluorophore conjugated WGA
lectins resulted in enhanced fluorescence in cancerous tissue compared to normal tissue. The fluorescence seen on the periphery of the
normal tissue specimen (B) is due to AF647-WGA staining of the stroma layer, which was exposed following resection. The color coded
intensity scale and the magnifications are indicated in the figure.
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was also used to obtain a measure of the camera background noise,
and the measured MFI's were recorded with the static background
noise subtracted. To quantify a measure of WGA binding affinity
between normal and cancerous tissue, the signal-to-noise ratio (SNR)
between those samples was determined by taking the MFI value from
the diseased tissue and dividing it by the MFI value from the normal
tissue; it should be noted that the same region-of-interest was used to
calculate MFI values for the normal and cancerous tissue. The SNR
for autofluorescence is the inverse of this definition as tumorFigure 3. Histology images of tissue in Fig 2. Biopsy specimens show
stain. Fig 3A shows the normal tissue epithelium whereas Fig 3B s
numerous large, dense and atypical nuclei with irregular patterning.autofluorescence is lower than normal tissue autofluorescence due to
lower NADH levels [24,25]; thus this SNR is the MFI of the normal
tissue divided by the MFI of the cancerous tissue. This SNR
calculation provides the most robust measure of differential
fluorescent values, since the samples were imaged together and no
other manipulation of the raw values were made.
Pathological Diagnosis
Following imaging, each sample received a unique label to remove
any trace of patient information so that the pathological diagnosis wasn in Fig 2 were confirmed normal and cancerous via a standard H&E
hows stage I squamous cell carcinoma, which is characteristic of
Similar histology results were obtained for all other patients.
Figure 4. Representative images of whole biopsies. Biopsy specimens (tumor and normal) derived from patients were labeled with
AF350-WGA and then imaged under white light (A) and fluorescence (B & C) in two different patients. Fig 4B is an overlay image taken with
the scientific camera whereas Fig 4C is an image taken with the digital camera. Again, localization of the lectin on the cancerous tissue is
seen. AF350-WGA results in fluorophore emission that is easily seen with the naked eye (C). The color coded intensity scale and the
magnifications are indicated in the figure.
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samples were then bisected so that a portion was fixed in
formaldehyde and paraffin embedded, and another could be used
for frozen section analysis for quick histological diagnosis. True
pathological diagnosis consisted of a routine hematoxylin and eosin
(H&E) stain performed and analyzed by a board certified pathologist.
The pathological diagnosis was then classified into the following three
categories: (1) normal, (2) dysplasia and (3) cancer with stage. All
specimens were then returned to the Pathology Department of the
Narayana Hrudayalaya Multispecialty Hospital and Mazumdar-Shaw
Cancer Center.
Statistical Analysis
Data are presented as mean ± SD. Statistical analysis of ex vivo
fluorescence measurements was conducted using a 2-tailed, paired
Student's t test. All statistical analyses were performed using a 95%
confidence interval, which relates to a P value b .05 being statisti-
cally significant.Figure 5. Distinction between the normal and tumor samples in
terms of signal to noise ratios (SNR) using AF350-WGA. The
cancerous tissue displayed statistically significantly higher fluores-
cence than the normal tissue with an average SNR of 5.88 ± 3.46
(P = .00046).Results
Fluorescence Imaging Using WGA Lectin
Fluorophore Conjugates
Both AF647 and AF350 conjugated WGA yielded similar binding
results. This can be seen in Figure 2 which shows white light
(Figure 2A and C), red light (Figure 2B), and UV (Figure 2D)
excitation images of cancerous and normal tissues from the same
patient stained with both fluorophore conjugates. The excised tissue
was stained with AF647-WGA while the smaller tissue biopsies, from
the same excised tissue specimen, were stained with AF350-WGA.
The fluorescence seen on the periphery of the normal tissue specimen
(B) is due to AF647-WGA staining of the stroma layer, instead of the
epithelial layer; the stroma layer was exposed due to tissue resection.
However, the clinical topical application of WGA will not concern
the deeper tissue layers and will only analyze epithelial glycan
expression profiles. Therefore, these recorded intensity measurements
were omitted from ROIs of epithelial fluorescence. Histological
evaluation of the tissue samples revealed normal epithelium
(Figure 3A) and stage I squamous cell carcinoma (Figure 3B) for
the normal and cancerous tissue samples, respectively. This shows it isTable 2. Summary of the data collected during experimentation.
PT Patient
#
AF350-WGA Fluorescence
(FWHM 40)
UV Autofluorescence (FWHM 40)
T N SNR T N SNR
22 1 1315.19 364.31 3.61 587.12 658.02 1.12
23 2 1255.65 320.82 3.91 217.18 407.83 1.88
25 3 2354.96 190.61 12.36 207.45 181.50 0.87
27 4 2341.97 344.11 6.81 804.92 1552.26 1.93
28 5 1377.93 458.09 3.01 459.84 577.40 1.26
29 6 3072.64 923.95 3.33 730.93 784.69 1.07
30 7 2164.93 265.50 8.15 568.341 743.62 1.31
AVE - - 5.88 - - 1.35
SD - - 3.46 - - 0.41
The WGA probe yielded statistically significantly greater fluorescence in cancerous tissue compared
to normal tissue (SNR of 5.88 ± 3.46, P = .00046). The UV autofluorescence was not statistically
significantly different than normal tissue (SNR of 1.35 ± 0.41, P = .098). The SNR of the AF350-
WGA probe was statistically significantly larger than the SNR for UV autofluorescence (P = .0049).
Figure 6.Molecular binding specificity experiment with the inhibitory sugar N-acetyl glucosamine. Biopsy specimens, tumor and normal,
were derived from the resection specimen of a single patient and incubated with inhibited (within the oval) and uninhibited AF350-WGA
conjugate. A sample of the tumor was not incubated with any WGA and kept as a control. The specimens were imaged under white light
(A) and fluorescence (B & C). Fig 6B is an overlay image taken with the scientific camera whereas Fig 6C is an image taken with the digital
camera. Pre-incubation of AF350-WGA with the inhibitory sugar resulted in a 3 fold decrease in fluorescence of the cancerous tissue;
however, this fluorescence was still greater than fluorescence from normal tissue incubated with uninhibited AF350-WGA. No incubation
withWGA resulted in very little fluorescence for the cancerous control sample. These results demonstrate that the lectin binding is indeed
molecularly specific to sialic acid residues that are overexpressed on cancerous tissue. The tumor and normal specimens, intensity scale
and magnification are indicated in the figure.
Table 3. Summary of paired biopsy sets listing anatomical site in the oral cavity and the pathological
diagnosis.
Patient Number Sex Age Anatomical Site Stage Pathological Diagnosis
1 M 50 BM I SCC/Normal
2 F 55 BM IV SCC/Normal
3 M 55 BM II SCC/Normal
4 M 70 FOM I SCC/Normal
5 F 56 BM I Dysplasia/Normal
6 M 61 BM I SCC/Normal
7 F 47 BM IV SCC/Normal
BM: Buccal Mucosa; FOM: Floor of Mouth; SCC: Squamous Cell Carcinoma.
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cancerous tissue utilizing different fluorophores conjugated to WGA.
Figure 4A shows a different set of biopsy samples visualized under
white light following treatment with the AF350-WGA probe. The
fluorescent lamp used for white light imaging may have caused
uneven tissue illumination, resulting in the cancerous tissue looking
brighter in Figure 4A. However, tissue appearance differences
between normal and diseased tissue is well established due to
increased cell density, protein amounts, etc. Typically, these lesions
are often times whiter in appearance which would have caused them
to appear brighter under white light imaging. Nevertheless, increased
probe fluorescence is noted on the tumor specimen and not the
normal specimen (Figure 4B), proving the specificity of the probe for
the overexpressed glycan residues on the tumor surface. Lastly,
Figure 4C shows a digital camera image of tissue biopsies incubated in
AF350-WGA to capture fluorescent images that would more
accurately demonstrate the conditions observed within a clinical
setting; this image shows the enhanced fluorescence is easily visible
with the naked eye.
Similar results were seen for all tissue samples tested with AF350-
WGA and are summarized in Figure 5 and in Table 2. Figure 5 shows
the patient/tissue samples' SNR for AF350-WGA testing. The
AF350-WGA fluorescence of the cancerous tissue was statistically
significantly higher than that of normal tissue with an average SNR of
5.88 ± 3.46 (P = .00046, Table 2). The differences observed amongst
the SNRs can be attributed to the fact that sialic acid overexpression is
dependent on patient variability, disease progression, cancer
aggressiveness, etc. However, it is important to note that all patients
displayed SNRs greater than 3. The UV autofluorescence of the
cancerous tissue displayed an average SNR of 1.35 ± 0.41 and was not
statistically significantly different than normal tissue (P = .098,
Table 2). The SNR of AF350-WGA was statistically significantly
larger than the SNR for UV autofluorescence (P = .0049, Table 2)
with it being at least double the ratio in all seven patients.
Inhibitory Sugar Experiments Indicate the Specificity
of the Assay
To further validate the specificity of the WGA binding conjugate,
inhibitory experiments were carried out with N-acetyl glucosaminewhich serves to block the available binding sites of WGA prior to
sample application. Pre-incubation of AF350-WGA with the sugar
resulted in a threefold decrease in fluorescence intensities of the
cancerous tissue (Figure 6), indicating that the soluble sugar
competitively inhibited the WGA from binding to the overexpressed
glycan residues on the cancerous cell surface. Interestingly, the
inhibited AF350-WGA still resulted in higher fluorescence intensity
values from the cancerous tissue when compared to the normal tissue
(Figure 6B and C). This clearly demonstrates that neoplastic tissue
exhibits a much higher content of overexpressed cell surface glycans
compared to normal tissue, further supporting WGA's specificity for
the overexpressed sialic acid on the cancerous cell surface. Lastly, the
cancerous and normal biopsies incubated with either uninhibited or
inhibited AF350-WGA resulted in greater fluorescence than the
control tumor sample that was not incubated with any AF350-WGA.
This demonstrates that the observed fluorescence from tissue stained
with the lectin conjugate is not a result of intrinsic tissue
autofluorescence at the excitation wavelength of 365nm.
Pathological Diagnosis
Histological analysis revealed that 4/7 patients had stage I cancer,
1/7 had stage II cancer, and 2/7 had stage IV cancer. Of the seven
patients, 6/7 exhibited squamous cell carcinoma while 1/7 exhibited
dysplasia. All normal biopsies were confirmed to be free from disease.
The histological results are summarized in Table 3. Histology pictures
for the tissue in Figure 2 can be seen in Figure 3. Here normal tissue
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verified as stage I squamous cell carcinoma (Figure 3B).
It should be noted that the effect of AF350 and AF647 lectin
binding on H&E staining was tested by comparing lectin labeled
slices with unlabeled control slices from the same biopsy set.
Comparison of these slices showed no effect of lectin labeling on
H&E staining (data not shown). Furthermore, H&E staining was
identical for normal and clinically abnormal tissue independent of the
degree of staining with Alexa Fluor lectin conjugates.
Discussion
The use of molecular and biochemical changes as a basis to develop early
detection methods of oral cancer were explored in this manuscript. The
lectin WGA was primarily chosen for this application as it has high
affinity for sialic acid and N-acetyl glucosamine residues which are
known to be overexpressed in neoplastic tissue due to aberrant
glycosylation [13,14,29–31]. Furthermore, the relative expression of
these sialic acid residues in the epithelium is suggested to be
representative of tumor prognosis [16,18,32]. The data presented here
demonstrate that WGA fluorophore probes can agglomerate on cancer
cells overexpressing these glycomolecules, successfully yielding statisti-
cally higher fluorescence in cancerous tissue than normal tissue.
Additionally, the WGA fluorophore probes resulted in a higher SNR
than tissue UV autofluorescence at 365nm. Furthermore, through
inhibitory binding studies with WGA it was shown that the lectin
binding is molecularly specific to these glycans since inhibited WGA
resulted in decreased tissue fluorescence, highlighting that theWGA is in
fact binding to cellular glycans overexpressed in cancerous tissues. Lastly,
this experiment showed that fluorescence intensity differences are not
due to tissue diffusion variations between normal and tumor tissues (i.e.
leaking vasculature or compromisedmucosa).Our data demonstrate that
the use of WGA fluorophore probes is a significant improvement over
current autofluorescent methods. This procedure provides reproducible
SNRs for reliably differentiating normal tissue from cancerous tissue in
the oral mucosa that can be viewed unaided by the naked eye.
Both exogenous fluorophores (AF647 and AF350) tested showed
similar results even though the fluorophores are on the opposite ends
of the visible spectrum. The AF647-WGA probe was used to initially
test the feasibility of cancer detection as there is negligible tissue
autofluorescence in the far-red and near-infrared spectrums [23],
providing a measure of confidence that the fluorescence obtained was
from the binding of the lectin to glycoconjugates. Additionally, near
infrared wavelengths can penetrate further into the tissue [33].
However, since we are imaging the probe on the superficial tissue
surface, light propagation into the tissue is not a concern and did not
seem to enhance the SNRs in this experiment. The disadvantage of
utilizing near‐infrared fluorophores is the fact that a camera and
narrow bandpass filtering is needed since visualization is outside of the
visible spectrum, and near‐infrared fluorophores exhibit small stokes
shifts. Previous work of ours detailed the use of AF647-WGA for oral
cancer detection; however, the data is not shown in this manuscript
(besides the single patient comparison of AF350-WGA and AF647-
WGA) since this paper focused on developing a clinically useful tool
without the need for complex filters and cameras. As such, most of the
presented data was with AF350-WGA, which allowed for fluorophore
emission easily visible to the naked eye. Furthermore, as the AF350 is
in the UV spectrum, there is more energy per photon which yields a
larger stokes shift for UV fluorophores; a larger stokes shift is
advantageous to allow for easier discrimination of excited and emittedlight. Combined, these features make the AF350-WGA more suitable
for clinical use as additional equipment is not required.
Previously, researchers have examined intrinsic fluorescent mole-
cules and tissue reflectance properties to differentiate between normal
and cancerous tissue. For example, commercially available devices
(VELscope, ViziLite, etc.) have been developed to analyze tissue
autofluorescence for cancerous tissue. However, these devices were
identified as ineffective adjuncts to current white light head and neck
exams as well as histological methods as they lack adequate specificity
and sensitivity to accurately diagnose oral cancer [34,35]. Similar
conclusions were seen in our data which showed suggestive
differences in autofluorescence between normal and cancerous tissue
at 365nm (P = .098). Another group demonstrated that fluorescently
labeled glucose preferentially localized in cancerous tissue due to
increased metabolic activity. This approach was favorable and lead to
a SNR of 3.7 [36]; however, this is lower than the SNR reported in
this manuscript (5.88). In a recent study by Bird-Leiberman, they
showed that alteration of cell surface glycans in Barret's esophagus
from dysplasia to adenocarcinoma can be effectively visualized using a
fluorophore bound to WGA [22]. The WGA binding to the altered
cell surface glycans was highly specific and aided in the discovery of
lesions that would have been missed during conventional endoscopy
[22]. The results presented by Bird-Leiberman et al. are very similar to
the data shown in this study, which confirms the use of lectin molecules
as potential markers of neoplasia in lesions that cannot be visualized
clinically in white light. Moreover, this approach can be used to
determine surgical boundaries in the oral cavity prior to tumor resection.
One of the limitations of the study has been the usage of the
permeation chemical DMSO. Although FDA approved for some
applications, it does have some minor side effects including skin rash,
nausea, and headache [37,38]. Another limitation is that tissue
samples were incubated with the WGA-fluorophore solution for 1
hour which would not be clinically feasible. These and other limitations
will be addressed through additional studies to determine the most
adequate composition of AF350-WGA solution for clinically relevant
cancer detection.
This study investigated the efficacy of fluorescence imaging using
topically applied lectin-fluorophore conjugates as compared to conven-
tional tissue autofluorescence in distinguishing tumor tissue. The results
revealed that the changes in glycosylation could differentiate normal
from cancerous tissues in the oral cavity with high SNRs. Therefore, this
technique seems promising as a non-invasive screening method for
premalignant and malignant mucosal tumors, and as a method for
defining surgical margins and monitoring cellular changes over time.
Provided technologies that target cancer on a molecular level, clinicians
could effectively recognize lesions in earlier stages, thereby enabling early
detection and treatment. To further evaluate this approach for oral cancer
screening, in vivo testing with a larger sample size needs to be performed
to obtain sensitivity and specificity values. Nevertheless, to the best of our
knowledge, the authors have, for the first time, demonstrated that topical
application of lectin probes to mucosal epithelial tissues followed by
molecular imaging of the tissues can be used to spatially differentiate
cancerous and normal tissue of the oral cavity.
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